FOXA1 and prostate carcinoma: It highlights the potential use of SNP rs9364554 as a biomarker to predict drug efficacy in precisely treating prostate cancer patients and lays the groundwork for further exploration into the therapeutic potential of targeting FOXA1 to improve drug efficacy in prostate cancer.